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John A. Halsall and Bryan M. Turner*Histone deacetylase inhibitors (HDACi) are in clinical trials against a variety of
cancers. Despite early successes, results against the more common solid
tumors have beenmixed. How is it that somany cancers, andmost normal cells,
tolerate the disruption caused by HDACi-induced protein hyperacetylation?
And why are a few cancers so sensitive? Here we discuss recent results
showing that human cells mount a coordinated transcriptional response to
HDACi that mitigates their toxic effects. We present a hypothetical signaling
system that could trigger and mediate this response. To account for the
existence of such a response, we note that HDACi of various chemical types are
made by a variety of organisms to kill or suppress competitors. We suggest that
the resistance response in human cells is a necessary evolutionary conse-
quence of exposure to environmental HDACi. We speculate that cancers
sensitive to HDACi are those in which the resistance response has been
compromised by mutation. Identifying such mutations will allow targeting of
HDACi therapy to potentially susceptible cancers.cancer; chromatin; deacetylase; epigKeywords:enetic drugs; evolution; histone
modification.201600070
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It is now almost 40 years since the first
demonstration that treatment of cells in
tissue culture with salts of butyric acid
(a short chain fatty acid, SCFA) caused
increased levels of histone acetyla-
tion [1]. This was accompanied by
slowed cell cycle progression [2] but
no dramatic, overall change in RNA
synthesis [3]. It was shown that hyper-
acetylation resulted from inhibition of
deacetylase activity [4]. These early
experiments demonstrated the rapid
turnover of histone acetate groups,BioEssays Published by WILEY Periodicals, Inc.
f the Creative Commons Attribution License, wh
medium, provided the original work is properlyand provided an invaluable method
for production of acetylated histones
for structural and functional analyses.
The observation was particularly excit-
ing in view of the possible link between
histoneacetylationand transcription [5],
and that low concentrations of butyrate
could induce differentiation of an eryth-
roleukemia cell line into non-dividing,
hemoglobin synthesizing cells [6].
These experiments all predated elu-
cidation of the role of histones in DNA
packaging, identification of enzymes
responsible for turnover of histone ace-
tates, formulation of the histone code
hypothesis and realization of the extraor-
dinary complexity of the processes by
which histone post-translational modifi-
cations regulate chromatin function
(reviewed in [7, 8]). But despite the vastly
increased amount of information at our
disposal, and increasingly sophisticated
technologies by which to generate even
more, fundamental questions posed
nearly 40 years ago about the functional
role of histone acetylation, remain unan-
swered [9]. The problem is particularly
acute in view of the increasing clinical
use of histone deacetylase inhibitors
(HDACi), both simple SCFA salts such
as sodium valproate, and more complex
reagents.
In this article, we ask how it is that
most normal cells are able to tolerate the
extreme hyperacetylation of histones
and other proteins induced by HDACi
and why just a few types of cancer are so
sensitive. If histone acetylation really iswww.bioessays-journal.com 1
ich
cited.
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control mechanisms, then its disruption
should be consistently lethal. To answer
this, we present recent evidence that
cells have an intrinsic, chromatin-based
transcriptional response that mitigates
the potentially deleterious effects of
HDACi. We present an evolutionary
rationale for the existence of such a
response, and speculate on how HDACi
might mediate chemical interactions
between divergent organisms. Predict-
ing how any particular cell, whether
normal or cancerous, is likely to re-
spond to HDACi, is an issue with
obvious relevance for improving the
clinical effectiveness of this family of
inhibitors.Histone deacetylase
inhibitors are effective in
treating certain cancers
In 2006, the US Food and Drug Adminis-
tration (FDA) approved the use of a
histone deacetylase inhibitor, suberoy-
lanilide hydroxamic acid (SAHA, mar-
keted by Merck as Zolinza), for the
treatment of cutaneous T-cell lymphoma
(CTCL). The drug is remarkably effective
against this rare cancer, as is the
structurally unrelated inhibitor depsi-
peptide, a bicyclic peptide marketed as
Romidepsin. More recently, two further
hydroxamic acid HDACis have also been
grantedFDAapproval,Belinostat against
peripheral T-cell lymphoma and Pano-
binstat,againstmultiplemyeloma.These
successes show that HDACi, as a class of
drugs, canbeeffective chemotherapeutic
agents [10, 11].
Recently, there has been a prolifera-
tion of trials testing HDACi against a
variety of cancers, often in combination
with other drugs, such as aza-cytidine (a
DNA methyltransferase inhibitor) and
Bortezomib (a proteasome inhibitor) [10,
12]. Inhibitors for which completed trials
have been reported, and the cancers
against which they have been tested,
are listed in Tables 1 and 2. Although
hematological malignancies remain the
major clinical targets for HDACi, several
have now been trialed against more
common solid tumors, including lung,
breast and prostate cancer (Tables 1 and
2). Results have been mixed; the
variability of response, both between2 Bioand within cancer types is striking, and
remains unexplained [13].
Understanding how HDACi affect
different cell types is complicated by
the fact that protein deacetylation is
carried out by a family of enzymes,
within which individual members differ
in their sensitivities to different HDAC
inhibitors. Fortunately, a substantial
body of research since purification
and characterization of the first HDAC
in 1996 [14] has provided valuable
insights into the HDAC family and the
factors that regulate its activities.HDACs are a diverse
enzyme family whose
activities depend on
associated proteins
There are 18 different HDACs in human
cells, split into four classes (reviewed
in [15]). Eleven of these enzymes, classes
I, IIa, IIb, and IV, have a very similar
catalytic site. Class III enzymes, the
sirtuins, are NAD dependent, and are
insensitive to all classes of HDACi in
clinical use [15, 16]. It is important to
remember that HDACs, despite their
name, act on a variety of proteins in
addition to histones, including tran-
scription factors, enzymes and HDACs
themselves [17].
Class I HDACs are nuclear enzymes
that are likely to be involved in main-
taining histone acetylation levels. The
catalytic activities of class IIa enzymes
are very low in vitro and seem to be
unnecessary for at least some of their in
vivo functions [18]. They shuttle be-
tween the cytoplasm and nucleus and
may play a structural role in complexes
involved in regulating chromatin func-
tion [19]. The class IIb enzymes act
primarily on cytoplasmic components
while the only class IV enzyme,
HDAC11, is present in low amounts
and is of uncertain function [20]. It is
important to note that levels of individ-
ual HDACs vary widely from one tissue
to another and the HDACs that consti-
tute the most promising targets for
therapy may depend on the tissue in
which the tumor originated.
Attempts have been made to estab-
lish the roles of the different HDACs in
processes relevant to cancer treatment,
such as growth control, differentiation,essays 38: 0000–0000, 2016 The Authors Bioand apoptosis. Knocking out HDACs 1–
4, 7, and 8 in mice is lethal during
development (E9.5–11) or the early post-
natal period, while knockouts of HDACs
5, 6, and 9 are viable [20]. Surprisingly,
complete deletion of any one of the class
I HDACs had no major effect on the
growth or viability of tumor cell lines,
despite their in vivo lethality [21]. How-
ever, knockout of both HDAC 1 and 2
resulted in rapid cell death, largely as a
result of aberrant mitosis. Significantly,
HDAC 1/2 -/- fibroblasts transformed
with H-Ras, did not form tumors when
injected into nude mice [21]. These
experiments show that HDACs 1 and 2
are key, redundant targets for suppres-
sion of tumor growth by HDACi.
HDACs1–3 are catalytically active
only when physically associated with
specific partner proteins. Four such
HDAC complexes have been isolated
and characterized, namely CoRest,
NuRD, Sin3 (each containing HDACs 1
and 2) and NCoR/SMRT, which contains
HDAC3 [22]. The complexes are responsi-
ble for the up- and/or down-regulation of
specific genes and are necessary for the
correct differentiation of various cell
types [23]. Further complexity is intro-
duced by structural studies showing that
HDAC activity of the NCoR and NuRD
complexes requires incorporation of a
molecule of D-myo-inositol 1,4,5,6 tetra-
kisphosphate (ins(1,4,5,6)P4), a crucial
mediator of intracellular signaling path-
ways [24]. A recent paper has introduced
a further level of HDAC regulation by
demonstrating complementary roles for
monomeric and polymeric nuclear actin
in regulation of HDAC1 and 2 [25].
Thus HDACs, collectively, have mul-
tiple substrates and are regulated at
multiple levels, including association
with other proteins, chemical modifica-
tion, and interaction with components
of intracellular signaling pathways.HDACi generally inhibit
several members of the
HDAC family
In view of the high degree of conserva-
tion of the HDAC catalytic site between
all but the class III (NAD dependent)
HDACs, it is not surprising that most
inhibitors target more than one family
member. The specificities of theEssays Published by WILEY Periodicals, Inc.
Table 1. Histone deacetylase inhibitors in clinical trials against cancer
Structural class Name HDACs inhibited Cancer type
Clinical trial
status
Benzamide 4SC-202 I AHM I
Chidamide (Epidaza,
HBI-8000)
HDAC1,2,3,10 PTCL Approved (Chn)
NSCLC II
CI994 HDAC1,3 NSCLC III
MuMy, Pan II
Entinostat (SNDX-275) HDAC1,2,3,9 AML, Br, Col, MDS, MM, NSCLC II
ALL, Lym I
Mocetinostat (MGCD0103) HDAC1,2,3,11 CLL, Lym, MDS II
NHL I
Carboxamide Abexinostat (PCI-24781) HDAC1,2,3,6,8,10 Sar, Lym II
Quisinostat (JNJ-26481585) I,II,IV CTCL II
Lym, MuMy, NSCLC, Ov I
Cyclic peptide Depsipeptide (Romidepsin) HDAC1,2,4,6 CTCL, PTCL Approved (US)
AML, Br, Col, Gli, MDS, MuMy, NHL,
NSCLC, RCC, SCLC, Thy
II
Lym, Pan I
Hydroxyacrylamide Resminostat
(4SC-201/RAS2410)
HDAC1,3,6 Col, HCC, HL II
Hydroxamic acid Belinostat (PXD101) I,II PTCL Approved (US)
AML, CTCL, Liv, NLH, MDS, Mes,
MuMy, NHL, NSCLC, Ov, Sar, Thy
II
AHM, Lym I
CUDC-101 I,II (þEGFR, HER2) Br, Gas, HNC, Liv, NSCLC I
Givinostat (ITF2357) I,II HL, MuMy, PCV II
Panobinostat (LBH589) I, II MuMy Approved (US)
CTCL, HL III
Br, MDS, Pr, TCL II
ALL, AML, CML, Col, MCL, NHL I
Pracinostat (SB939) I,IIa, HDAC6, IV AML, MDS, Pr, Sar II
SHP-141 Not available CTCL I
Tefinostat (CHR-2845) Not available AHM I
Trichostatin A I, II
Vorinostat (SAHA) I, IIa, IIb, IV CTCL Approved (US)
Mes, MuMy III
AML, ALL, Br, GBM, HL, MDS, MM,
NHL, NSCLC, Pr, RCC, Sar
II
APL, Col, DLBCL, NBM, Pan I
Isothiocyanate Sulforaphane (brocolli) Not available Br, Pr II
Short chain
fatty acid
Pivanex (AN-9) I, IIa NSCLC II
Valproic acid I, IIa AML, HNC, MDS, Mes, Sar, SCLC II
CLL, Lung, MDS, NSCLC, Ov, SLL I
Inhibitors are grouped by their basic chemical structure. The HDACs against which specific inhibitors act are shown, where
known, along with the cancers against which they are being trialed and the furthest stage of trial reached.
HDAC classes: Class I, HDAC 1, 2, 3, 8; Class IIa, HDAC 4, 5, 7, 9; Class IIb, HDAC 6, 10; Class III, SIRT1-7 (these NAD-
dependent deacetylases are not inhibited by HDACi); Class IV, HDAC 11. Source: ClinicalTrials.gov (NIH)
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Table 1. This broad specificity makes it
difficult to interpret the results of
inhibitor treatment in terms of precise
biochemical mechanisms. Attempts
have been made, with some success, to
synthesize derivatives specific for indi-
vidual HDACs and one such (a benzam-
ide, 4SC-202) [26, 27] is in a phase I
clinical trial (Table 1). However, the
functional redundancy of HDACs, par-
ticularly class I enzymes [20, 21], may
reduce the clinical effectiveness of
enzyme-specific inhibitors. It is alsoBioessays 38: 0000–0000, 2016 The Authorsworth noting that the specificities of
individual HDACs have been determined
by using pure, recombinant enzymes
against artificial substrates. The catalytic
activity of recombinant HDACs is ex-
tremely low and unlikely to reflect the in
vivo situation where the enzyme itself
can be part of different multi-protein
complexes and exposed to the various
factors (such as inositol phosphates) that
modify its activity. An indirect, mass-
spectrometry-based assay has been de-
vised to examine the in vivo sensitivities
of the different HDAC complexes toBioEssays Published by WILEY Periodicals, Inc.common inhibitors [28]. Though techni-
cally challenging, such approaches may
provide a deeper understanding ofHDAC
inhibitor sensitivities.Why most cells are
tolerant of HDACi-induced
hyperacetylation
A recent paper from the authors’
laboratory [29], addresses the question
of why cells are usually so tolerant of3
Table 2. Abbreviations of cancer types used in Table 1 and the number of HDACi compounds which have completed trials or
are approved for each cancer
Abbreviation Cancer n Abbreviation Cancer n
AHM Advanced hematological malignancies 3 MCL Mantle cell lymphoma 1
ALL Acute lymphoblastic leukemia 3 Mes Mesothelioma 3
AML Acute myeloid leukemia 7 MM Malignant melanoma 2
APL Acute promyelocytic lymphoma 1 MuMy Multiple myeloma 7
Br Breast 6 NBM Neuroblastoma 1
CLL Chronic lymphocytic leukemia 1 NHL Non-hodgkins lymphoma 5
CML Chronic myeloid leukemia 1 NSCLC Non-small cell lung cancer 10
Col Colorectal 5 Ov Ovarian 3
CTCL Cutaneous T-cell lymphoma 6 Pan Pancreatic 3
DLBCL Diffuse large B-cell lymphoma 1 PCV Polycythemia vera 1
Gas Gastric cancer 1 Pr Prostate 4
GBM Glioblastoma multiforma 1 PTCL Peripheral T-cell lymphoma 3
Gli Glioma 1 RCC Renal cell carcinoma 2
HCC hepatocellular carcinoma 1 Sar Sarcoma 5
HL Hodgkins lymphoma 3 SCLC Small cell lung carcinoma 1
HNC Head and neck cancer 2 SLL Small lymphocytic lymphoma 1
Liv Liver 2 TCL T-cell lymphoma 1
Lung Lung 1 Thy Thyroid 2
Lym Lymphoma 6
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tion. How do they deal with the
disruption of fundamental cell func-
tions that would be expected to ensue?
To address this, attempts were made
to identify the earliest transcriptional
and epigenomic responses to HDACi.
Human lymphoblastoid cells were ex-
posed to two chemically different
HDACi (SAHA and sodium valproate)
for 30, 60, and 120minutes At this early
stage, and for both inhibitors, cells
were found to undergo a progressive
and coordinated change in expression
of a small and distinctive set of genes.
Growth-promoting cytokines were
down-regulated, presaging a later slow-
ing of cell growth, while there was a
rapid up-regulation of genes encoding
DNA binding proteins and transcription
factors. But the most striking response
was the consistent and severe down-
regulation of genes encoding compo-
nents of the six enzyme complexes
responsible for protein acetylation, the
lysine acetyltransferases, KATs [17].
The rapid depletion of KAT complex
components inevitably diminishes the
aberrant acetylation of histones and
other proteins when the deacetylating
enzymes are blocked. KAT and HDAC
complexes have both been shown to
target the acetylated promoters of active
genes [30], so KAT depletion would be
expected to counter the effects of HDACi
at those loci where histone acetylation
is associated with gene expression. We4 Biopropose that this transcription-based
response allows the cell to reduce, and
eventually reverse, protein hyperacety-
lation at critical regulatory regions,
thereby reducing the epigenetic disrup-
tion caused by HDACi.
It is notable that, even at the earliest
time points, there was no consistent
association between increased histone
acetylation at transcription start sites
and increased gene expression. This
indicates that histone hyperacetylation,
at least at the three lysines studied so
far, does not drive increased gene
expression in this system, in agreement
with previous studies [31–34]. However,
it is striking that the genes that change
expression in response to HDACi,
whether up- or down-regulated, are
packaged in highly acetylated chroma-
tin [29]. It seems that histone acetylation
helps provide a chromatin context
within which genes are able to change
their transcriptionl state in response to
HDACi, and perhaps other regulatory
signals.
Surprisingly, the most substantial
change in histone modification we ob-
servedwas an increase in the levels of the
Polycomb-associated silencing mark
H3K27me3, specifically at transcription
start sites and mostly at genes whose
expression did not change [29].The
change in H3K27me3 levels at TSS was
shown to be required for the short term,
HDACi-induced changes in transcription
at some loci. A chemical inhibitor of theessays 38: 0000–0000, 2016 The Authors Bioenzyme responsible for H3K27 methyla-
tion, EZH2, prevented the up- or down-
regulation of selected groups of genes
[29]. How the changes in H3K27me3 are
triggered, and how they influence the
response to HDACi, are questions that
require further investigation.Does a reversibly
acetylated non-histone
protein control the
response to HDACi?
The lack of association between changes
in histone acetylation and transcription
over the early stages ofHDACi treatment,
suggests that histones themselves are
not the primary driver of early transcrip-
tional change. What is? In Fig. 1, we
present a model in which the acetylated
and non-acetylated isoforms of a master
regulatorproteinenhance theexpression
of different sets of genes. The relative
expression levels of these genes are
dependent on the balance between
acetylated and non-acetylated isoforms.
HDACi cause the balance to shift dra-
matically toward the acetylated form,
resulting in up-regulation of one set of
genes and down-regulation of the other
(Fig. 1). The response is self-limiting in
that the universal down-regulation of
KAT complex components by HDACi
will diminish acetylation of the primary
sensor, thereby increasing the non-Essays Published by WILEY Periodicals, Inc.
Figure 1. A hypothetical primary sensor and signaling cascade by which cells respond to
environmental HDACi. The proposed primary sensor protein (blue ovals) is subject to
acetylation (red disc) at one or more lysines. The balance between acetylated and non-
acetylated isoforms is determined by the activities of a lysine acetyltransferase (KAT) and
deacetylase (HDAC). Each isoform is responsible for regulating the activities of a set of genes
with distinctive functional associations (ontologies), as indicated (pink or green shading). It
does this by initiating a series of secondary signals (a signaling cascade) that ultimately
results in transcriptional activation at all target genes through induced (or activated)
chromatin binding proteins (gene regulators, blue, green, or red shapes). HDAC inhibitors tip
the balance of the primary sensor toward the acetylated isoform, resulting in increased
expression of the genes under its control, with reduced expression of genes regulated by
the non-acetylated (now diminished) isoform. Genes up- or down-regulated by HDACi have
been shown to be packaged in hyperacetylated chromatin, presumably to maintain an open
chromatin structure accessible to regulatory factors. The model is based on experimental
data presented in Halsall et al. [29].
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scription of KAT complex components
(Fig. 1). As things stand, the model is
entirely hypothetical. Experiments are
needed to identify the primary sensor
protein, the KAT and HDAC involved in
its acetylation, the steps in the signal
cascades that link the sensor to specific
sets of genes and the chromatin-binding
proteins that finally mediate the ob-
served changes in gene expression.
Depending on the number of steps in
the signal cascades, it is likely that
multiple gene regulatory proteins are
involved for both down- and up-regu-
lated genes (Fig. 1). Some proteins may
be used for both sets of genes. It is
important that both signal cascades are
responsible for supporting transcription
of their respective sets of target genes.
Thus, the down-regulation of KAT genes
and others in response to HDACi, is due
to diminution of this positive transcrip-
tional control, rather than active down-
regulation.
The components of the signal cas-
cades triggered by the primary sensor,Bioessays 38: 0000–0000, 2016 The Authorsand the chemical changes involved,
remain to be determined, but could
involve phosphorylation, mediated by
kinases and phosphatases as in many
other signaling pathways, or other
reversible modifications, including pro-
tein acetylation. In the latter case, the
involvement of Class III deacetylases
would protect the cascade from disrup-
tion by HDACi, to which these enzymes
are resistant [16]. It has become clear
that reversible lysine acetylation is a key
regulator of enzyme function and me-
tabolism in both eukaryotic cells and
bacteria [35–37].HDACi are natural
products that can kill or
manipulate competing
organisms
It is, at first sight, surprising that human
cells have the ability to mount such a
carefully calibrated response to various
inhibitors of a specific enzyme family.BioEssays Published by WILEY Periodicals, Inc.However, the fact that so many HDACi
are natural products, suggests an evo-
lutionary rationale through which these
findings are readily explained.
HDACi of various chemical shapes
and sizes are secreted by a wide range
of organisms, often to kill, or at least
suppress the growth of, competing life
forms, (reviewed by Salvador and
Luesch [38]). Some examples are pre-
sented in Table 3. Short chain fatty
acids, all broad spectrum HDAC inhib-
itors, are prolific by-products of bacte-
rial metabolism [39, 40]. Other,
chemically more complex, HDACi seem
to be specifically synthesized. The first
hydroxamic acid-based HDAC inhibitor
to be identified, Trichostatin A (TSA), is
secreted by selected species of bacteria
and is an antifungal antibiotic [41, 42].
Three types of bacterial HDACi based
on a cyclic depsipeptide chemical
backbone have been identified, FK228/
Romidepsin [43], spiruchostatin [44]
and largazole [45, 46]. The organisms
they act against remain to be identified,
though fungi are likely targets (Table 3).
Most fungal species seem to be
resistant to HDACi, though mechanisms
of resistance have only rarely been
reported [47], and some even make their
own. Examples include the linear poly-
ketide depudecin [48] and the cyclic
tetrapeptides HC-toxin [47, 49], and
Trapoxin [50]. Another fungal HDACi,
apicidin (a cyclic tetrapeptide made by
Fusarium spp.) specifically kills some
epicomplexan parasites (e.g. Plasmo-
dium berghei) [51, 52]. In a survey of 52
Fusarium isolates, only one produced
apicidin [53]. Some more complex,
multicellular eukaryotes also secrete
HDACi.Marine sponges synthesize HDACi
based on either a cyclic tetrapeptide
backbone (azumamides) [54] or bromotyr-
osine (Psammaplin A) [55–57], and may
serve to deter micro-organisms sharing
the same aquatic environment. The iso-
thiocyanate-basedHDACisulforaphane, is
produced by cruciferous plants such as
broccoli [58] and first became of interest
because of its ability to suppress the
growth of transformed cells in tissue
culture [58–60]. It remains to be shown
how this inhibitor, and HDACi in general,
mightbe involvedin thecancer-preventing
effects of cruciferous vegetables and
other dietary components [60–63].
Competition for space and resources
in the microbial world is often intense,5
Table 3. Natural products that act as histone deacetylase inhibitors
Inhibitor Chemical type Source organism Target organism References
Butyrate et al. Short chain fatty acid Most bacteria Eukaryotic cells [4]
Trichostatins Hydroxamic acid
derivatives
Bact; Streptomyces hygroscopicus Fungi (Trichophyton,
Aspergillus)
[41, 42]
FK228 (Romidepsin) Cyclic depsipeptide Bact; Chromobacterium violaceum Fungi? [43]
Spiruchostatin Cyclic depsipeptide Bact; Pseudomonas chloroaphilis Fungi? [44]
Largazole Cyclic depsipeptide Marine cyanobacterium (Symploca sp) unknown [45, 46]
Depudecin Linear polyketide Fungus (Alternaria brassicicola) unknown [48]
HC toxin Cyclic tetrapeptide Plant fungus (Cochliobolus carbonum) Green plants [47, 49]
Trapoxins Cyclic tetrapeptide Fungus (Helicoma ambiens) unknown [50]
Apicidin Cyclic tetrapeptide Fungus (Fusarium pallidoroseum) Apicomplexan parasites [51–53]
Azumamides Cyclic tetrapeptide Marine sponge (Mycale izuensis) unknown [54]
Psammaplin A Linear bromotyrosine Marine sponge (Psammaplysilla sp) unknown [55, 56]
Sulforaphane Isothiocyanate Cruciferous plants (eg broccoli) Pathogenic fungi? [58, 59]
The table shows the basic chemical structures of naturally occurring HDACi, organisms that make them and, where known,
the organisms against which they act in vivo. Detailed chemical structures for the inhibitors listed can be found in the review
by Salvador and Luesch [38].
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infinite variety of coping strategies have
evolved. The energy and resources that
some organisms devote to synthesizing
sometimes chemically complex deace-
tylase inhibitors is presumably justified
by the selective advantage they confer.
The processes by which bacterial HDACi
kill or deter competing organisms
remain to be established, but it is likely
to be important that fungi and protists
(eukaryotes) have chromatin-based epi-
genetic control systems that bacteria
(prokaryotes) lack.Eukaryotic chromatin-
based control systems
provide a likely target for
manipulation by
prokaryotes
All life forms on earth consist of one or
another of just twocell types,prokaryotic
(bacteria and archaea) and eukaryotic
(everything else, including all complex
multicellular life forms). Though derived
from a common ancestor [64], the two
cell types are qualitatively different.
Eukaryotes are classically distinguished
by possession of a nuclear envelope,
microtubules, and mitochondria (or
equivalent) [65]. In addition, although
prokaryotes have histone-like proteins
that bind DNA [66], only eukaryotes
package their DNA as chromatin, which
invariably is, or once was [67], based on
the canonical eight-histone nucleosome6 Biocore particle [7, 68]. Thus, chromatin,
nucleosomes and epigenetic control
systems based on chromatin modifica-
tions, are uniquely eukaryotic. In this
respect, they are likely targets for com-
peting prokaryotes. We suggest that the
HDACi secreted by somebacteria provide
one example of this targeting.
Eukaryotes would be expected to
have evolved responses to environmen-
tal HDACi, and we suggest that the
transcription-based resistance mecha-
nism present in human cells is an
example of this [29]. As a competitive
strategy, the secretion of HDACi will
succeed only while the competing
species are susceptible. Once they
become resistant, new strategies are
required. This may explain why most
bacteria do not secrete, or are not
known to secrete, HDACi, and why
most eukaryotes seem resistant to their
effects.
The resistance response to HDACi
may be evolutionarily very ancient. It is
estimated that the first prokaryotic life
forms emerged about 3.5 billion years
ago, 1 billion years or so after the planet
was formed [69]. The emergence of the
first eukaryotes is hard to establish, but
is unlikely to be more than 2 billion
years ago, perhaps much less [70]. The
first eukaryotes emerged into ecosys-
tems dominated by prokaryotes, who
would have used all means at their
disposal to see off the new competitors;
targeting their evolving, but uniquely
eukaryotic, chromatin, and epigenetic
signaling networks would be a promis-
ing approach (Fig. 2).essays 38: 0000–0000, 2016 The Authors BioEvolution generally proceeds by small
steps, by selection of small mutational
changes to existing systems. The devel-
opment, by early eukaryotes, of defen-
sive strategies to cope with prokaryotic
HDACi, must have proceeded in the
same way. In this respect, the simple
model presented in Fig. 1 suggests a
possible evolutionary pathway for the
establishment, and progressive im-
provement, of a resistance response.
All cells have systems by which they
maintain metabolic homoeostasis in the
face of environmental change and their
own growth and reproductive cycles.
The signal cascades shown in Fig. 1
could be viewed as components of a
homeostatic system for maintenance of
levels of a key metabolite, acetylCoA.
The intracellular concentration of ace-
tylCoA has been shown to regulate
levels of protein acetylation [36, 71],
and the primary sensor postulated in
Fig. 1 could have evolved from a sensor
used to monitor the concentration of
acetylCoA and regulate expression of
genes encoding acCoA-producing or or
acCoA-metabolising enzymes.
It would be wrong to assign the
prokaryote-eukaryote interactions pro-
posed here to the evolutionary past. We
live in a world in which prokaryotes are
ubiquitous, and even, by some mea-
sures, the predominant life form [72].
The human body is host to a variety of
bacterial species, some of which are
closely involved in key physiological
functions, and are disrupted in dis-
ease [73]. For example, colonic bacteria
give rise to millimolar concentrations ofEssays Published by WILEY Periodicals, Inc.
Figure 2. How a resistance response to histone deacetylase inhibitors (HDACi) might
influence both evolution of eukaryotes and response of tumor cells to chemotherapy. We
propose that eukaryotes have evolved a response that allows them to deal with the
hyperacetylation caused by environmental (often bacterial) HDACi (upper part). Cancer cells
in which this response remains intact can resist chemotherapeutic HDACi, whereas those in
which the response has been compromised, either by mutation or through additional drug
treatment, are killed, leading to a period of remission (lower part).
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the mammalian large intestine [74–77].
Cells of the colonic epithelium, includ-
ing differentiating stem cells involved in
replacement of the surface layer, must
therefore accommodate inhibitory con-
centrations of bacterial HDACi. Given
the subtlety with which prokaryotes
can influence patterns of gene expres-
sion in neighbors through chemical
signals [78], this is unlikely to be the
only situation in which endogenous
micro-organisms influence our epige-
netic systems [73]. Nor is it likely that
HDACs are the only targets.Conclusions
This article began with a description of
the potential value of HDACi as chemo-
therapeutic drugs, progressed through
the possible influences of HDACi in the
co-evolution of prokaryotic and eukary-
otic micro-organisms, and has finished
by highlighting the ongoing chemical
interactions between complex eukar-
yotes (including ourselves) and the
microbial world. This summary returns
to where we started, by noting that the
existence of a resistance response to
HDACi, and its evolutionary prove-
nance, has clinical implications. Certain
cancers may be sensitive to HDACiBioessays 38: 0000–0000, 2016 The Authorsbecause their resistance mechanism
has been disrupted (Fig. 2), perhaps
by mutation of one or more of its
essential genes, or components of the
(as yet hypothetical) primary sensor or
signal cascade (Fig. 1). Identification of
such mutations will help target individ-
ual cancers susceptible to HDACi.
Similarly, combining HDACi with drugs
that undermine the resistance mecha-
nism specifically in cancer cells, may
open the way to more successful
treatment of currently refractory can-
cers through combination therapy. It
will also be interesting to search for
other pathways by which prokaryotic
metabolites might dysregulate epige-
netic control systems peculiar to eukar-
yotes, and to ask by what means
eukaryotes defend themselves against
such manipulation. Understanding
these interactions may be crucial in
maximizing the clinical benefit of the
many chemotherapeutic drugs based on
natural products.Acknowledgment
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